Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists

Clinical and Experimental Immunology

Volumn 176, Issue 3, 2014, Pages 410-417

  Sauzullo, I ^a   Scrivo, R ^b   Mengoni, F ^a   Ermocida, A ^a   Coppola, M ^c   Valesini, G ^b   Vullo, V ^a   Mastroianni, C M ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Flow cytometry; Latent infection; Polyfunctional T cells; TNF antagonists; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIGEN SPECIFICITY; ARTICLE; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE RELEASE; DIAGNOSTIC KIT; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERFERON PRODUCTION; LATENT TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

FLOW CYTOMETRY; LATENT INFECTION; POLYFUNCTIONAL T CELLS; TNF ANTAGONISTS; TUBERCULOSIS;

ADULT; AGED; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTRACELLULAR SPACE; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTORS; YOUNG ADULT;

EID: 84899048806     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12290     Document Type: Article

References (36)

1. Gómez-Reino JJ, Carmona L, Rodríguez V etal. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48:2122-2127.
2. Keane J, Gershon S, Wise RP etal. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-1104.
3. Wallis RS, Broder MS, Wong JY etal. Granulomatous infection diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265.
4. Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests - TST and IGRA - for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71:1757-1760.
5. Sauzullo I, Mengoni F, Scrivo R etal. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010; 14:834-840.
6. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLOS ONE 2012; 7:e32482.
7. Hamdi H, Mariette X, Godot V etal. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:R114.
8. Chen DY, Shen GH, Hsieh TY etal. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59:800-806.
9. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 2008; 67:84-90.
10. Scrivo R, Sauzullo I, Mengoni F etal. Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 2013; 40:157-165.
11. Zwerling A, van den Hof S, Scholten J etal. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012; 67:62-70.
12. Sauzullo I, Mengoni F, Marocco R etal. IFN-γ release assay for tuberculosis in psoriasis patients treated with TNF antagonists: in vivo and in vitro analysis. Br J Dermatol 2013; 169:1133-1140.
13. Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2011; 29:790-794.
14. Garcovich S, Ruggeri A, D'Agostino M etal. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012; 26:1572-1576.
15. Kim KH, Lee SW, Chung WT etal. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 2011; 31:271-278.
16. Chen DY, Shen GH, Chen YM etal. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF (alpha) inhibitors: the utility of IFN (gamma) assay. Ann Rheum Dis 2012; 71:231-237.
17. Xie X, Chen JW, Li F, Tian J, Gao JS, Zhang D. A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy. Clin Exp Med 2011; 11:155-161.
18. Klein M, Jarosová K, Forejtová S etal. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clin Exp Rheumatol 2013; 31:111-117.
19. + T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40:2211-2220.
20. Sester U, Fousse M, Dirks J etal. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLOS ONE 2011; 6:e17813.
21. Lee J, Lee SY, Won DI etal. Comparison of whole-blood interferon-γ assay and flow cytometry for the detection of tuberculosis infection. J Infect 2013; 66:338-345.
22. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-247.
23. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V etal. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-1772.
24. Tesfa L, Koch FW, Pankow W etal. Confirmation of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incubation of peripheral blood T cells with an ESAT-6-derived peptide pool. Cytometry B Clin Cytom 2004; 60:47-53.
25. Hughes AJ, Hutchinson P, Gooding T etal. Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin Exp Immunol 2005; 142:132-139.
26. + T lymphocytes as a diagnostic tool for tuberculosis. Int Arch Allergy Immunol 2007; 143:1-9.
27. Leung WL, Law KL, Leung VS etal. Comparison of intracellular cytokine flow cytometry and an enzyme immunoassay for evaluation of cellular immune response to active tuberculosis. Clin Vaccine Immunol 2009; 16:344-351.
28. Won DI, Park JR. Flow cytometric measurements of TB-specific T cells comparing with QuantiFERON-TB gold. Cytometry B Clin Cytom 2010; 78:71-80.
29. Sargentini V, Mariotti S, Carrara S etal. Cytometric detection of antigen-specific IFNgamma/IL-2 secreting cells in the diagnosis of tuberculosis. BMC Infect Dis 2009; 9:99-109.
30. Streitz M, Fuhrmann S, Powell F etal. Tuberculin-specific T cells are reduced in active pulmonary tuberculosis compared to LTBI or status post BCG vaccination. J Infect Dis 2011; 203:378-382.
31. Petruccioli E, Petrone L, Vanini V etal. IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis. J Infect 2013; 66:475-486.
32. + T cell responses discriminate between latent infection and active disease. Nat Med 2011; 17:372-376.
33. + T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 2011; 41:2925-2936.
34. Day CL, Mkhwanazi N, Reddy S etal. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008; 197:990-999.
35. Gardam MA, Keystone EC, Menzies R etal. Anti-tumor necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003; 3:148-155.
36. Seder RA, Darra PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258.